This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks.com featured highlights include QuantumScape, Civeo and Agenus
by Zacks Equity Research
QuantumScape, Civeo, and Agenus show sharp earnings acceleration, signaling potential upside before Wall Street catches on.
QuantumScape & 2 Other Stocks to Buy for Earnings Acceleration
by Tirthankar Chakraborty
QS, CVEO, and AGEN show strong earnings acceleration this month - often a signal of stock price momentum ahead.
Is CVS Health (CVS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how CVS Health (CVS) and Agenus (AGEN) have performed compared to their sector so far this year.
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
by Zacks Equity Research
Shares of Viking slide after Q2 loss widens to 58 cents per share on rising R&D and nil revenues, missing estimates by 14 cents.
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
by Zacks Equity Research
AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.
MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights
by Zacks Equity Research
Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity through 2044.
AstraZeneca Meets All Key Goals in Phase III Hypertension Study
by Zacks Equity Research
AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.
Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA
by Zacks Equity Research
RARE faces regulatory setback as FDA issues a CRL for UX111, delaying approval of the MPS IIIA gene therapy until 2026.
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Agenus (AGEN) and CVS Health (CVS) have performed compared to their sector so far this year.
Agenus (AGEN) Surges 19.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Agenus (AGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?
by Zacks Equity Research
KalVista jumps 36% in a week after the FDA clears Ekterly, the first oral on-demand therapy for hereditary angioedema.
Zacks.com featured highlights Yext, Agenus and NCR Voyix
by Zacks Equity Research
VYX, AGEN and YEXT show powerful earnings acceleration for 2H25, signaling strong potential for price momentum ahead.
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study
by Zacks Equity Research
Shares of ProKidney jump 515% after its kidney cell therapy shows strong efficacy in a Phase II diabetes-related CKD study.
3 Top Earnings Acceleration Stocks to Buy for 2H25
by Tirthankar Chakraborty
Yext, Agenus and NCR Voyix show accelerating earnings growth, making them standout picks for the second half.
Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli
by Zacks Equity Research
APLS stock jumps after inking a $300M royalty deal with Sobi for Aspaveli, bolstering its cash position and pipeline prospects.
Biogen Begins Phase III Felzartamab Study for Third Kidney Disease
by Zacks Equity Research
BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with no approved therapies.
Moderna Stock Gains on Encouraging Flu Vaccine Data
by Zacks Equity Research
MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.
RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome
by Zacks Equity Research
Ultragenyx Pharmaceuticals' GTX-102 earns FDA Breakthrough status after early data shows sustained progress in Angelman syndrome patients.
Are Medical Stocks Lagging CVS Health (CVS) This Year?
by Zacks Equity Research
Here is how CVS Health (CVS) and Agenus (AGEN) have performed compared to their sector so far this year.
KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study
by Zacks Equity Research
Krystal Biotech rises 4% after dosing begins in a phase III study of KB803 eye drops to treat rare DEB-related corneal damage.
Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU
by Zacks Equity Research
AMRN jumps 27% after inking an exclusive EU licensing deal with Recordati to expand Vazkepa's reach and cut costs.
Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag
by Zacks Equity Research
Sanofi's riliprubart gets FDA orphan drug status for organ transplant rejection, unlocking key development perks.
CHMP Backs NVO's Ozempic EU Label Update for Cardiovascular Indication
by Zacks Equity Research
CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients with PAD.
FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer
by Zacks Equity Research
FDA expands AstraZeneca's Datroway label, making it the first TROP2-directed lung cancer therapy approved in the United States.
J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications
by Zacks Equity Research
JNJ wins CHMP backing for Darzalex and Imbruvica in new blood cancer uses, paving the way for first-in-class approvals.